JPMorgan initiated coverage of Enanta (ENTA) with an Overweight rating and $17 price target The firm cites the recent Phase 2b data for zelicapavir in respiratory syncytial virus for the positive view. The viral infection has significant unmet need and the study showed faster symptom reduction in the overall population, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA: